# Invivyd Inc. (IVVD)

Source: https://www.quantisnow.com/company/IVVD
Generated: 2026-11-12T07:47:32.942Z

- Ticker: IVVD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- SEC CIK: 0001832038

## Latest IVVD news and filings

- 2026-11-03 12:01 UTC [Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6768395)
- 2026-10-21 11:01 UTC [Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026](https://www.quantisnow.com/insight/invivyd-presents-vms063-a-potential-best-in-class-monoclonal-antibody-candidate-for-6752828)
- 2026-10-14 11:01 UTC [Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome](https://www.quantisnow.com/insight/invivyd-and-the-spear-study-group-announce-initiation-of-flintlock-6745818)
- 2026-10-05 11:01 UTC [Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6735873)
- 2026-09-29 11:26 UTC [SEC Form 8-K] [Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/invivyd-inc-filed-sec-form-8-k-other-events-financial-statements-6728366)
- 2026-09-29 11:01 UTC [Earnings Date] [Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311](https://www.quantisnow.com/insight/invivyd-announces-positive-topline-results-from-liberty-phase-3-study-6728331)
- 2026-09-08 11:01 UTC [Conference Announcement] [Invivyd to Participate in Upcoming September Investor Conferences](https://www.quantisnow.com/insight/invivyd-to-participate-in-upcoming-september-investor-conferences-6707380)
- 2026-09-03 11:01 UTC [Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6704153)
- 2026-09-02 20:40 UTC [SEC Form 4] [SEC Form 4 filed by Director Sheffield Ian](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sheffield-ian-6703502)
- 2026-09-02 20:40 UTC [SEC Form 3] [SEC Form 3 filed by new insider Sheffield Ian](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-sheffield-ian-6703499)
- 2026-09-01 22:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Elia Marc](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-elia-marc-6701951)
- 2026-09-01 11:10 UTC [SEC Form 8-K] [Invivyd Inc. filed SEC Form 8-K: Leadership Update, Other Events](https://www.quantisnow.com/insight/invivyd-inc-filed-sec-form-8-k-leadership-update-other-events-6700487)
- 2026-09-01 11:01 UTC [Leadership Update] [Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY](https://www.quantisnow.com/insight/invivyd-appoints-chairman-marc-w-elia-as-chief-executive-officer-6700465)
- 2026-08-19 00:10 UTC [SEC Form 4] [Chief Financial Officer Duke William E. converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/chief-financial-officer-duke-william-e-converted-options-into-102000-6687502)
- 2026-08-19 00:10 UTC [SEC Form 4] [Chief Human Resources Officer Green Julie converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) to satisfy tax liability](https://www.quantisnow.com/insight/chief-human-resources-officer-green-julie-converted-options-into-102000-6687501)
- 2026-08-19 00:10 UTC [SEC Form 4] [Chief Scientific Officer Allen Robert D. Iii sold $29,296 worth of shares (37,722 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 56% to 178,765 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-scientific-officer-allen-robert-d-iii-sold-29296-worth-6687500)
- 2026-08-19 00:10 UTC [SEC Form 4] [Chief Legal Officer, Secretary Andersen Jill converted options into 170,000 shares and sold $52,781 worth of shares (67,962 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 56% to 283,774 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-legal-officer-secretary-andersen-jill-converted-options-into-170000-6687499)
- 2026-08-19 00:10 UTC [SEC Form 4] [Chief Commercial Officer Lee Timothy Edward sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 52% to 178,937 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-commercial-officer-lee-timothy-edward-sold-31671-worth-of-6687498)
- 2026-08-17 20:05 UTC [SEC Form 144] [SEC Form 144 filed by Invivyd Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-invivyd-inc-6684924)
- 2026-08-14 21:20 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Invivyd Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-invivyd-inc-6683722)
- 2026-08-13 20:14 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Invivyd Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-invivyd-inc-6680570)
- 2026-08-13 20:11 UTC [SEC Form 8-K] [Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/invivyd-inc-filed-sec-form-8-k-results-of-operations-and-6680513)
- 2026-08-13 20:05 UTC [Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/invivyd-reports-second-quarter-2026-financial-results-and-recent-business-6680236)
- 2026-08-04 20:15 UTC [SEC Form 4] [SEC Form 4 filed by CMO and Chief Epidemiologist Mina Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-cmo-and-chief-epidemiologist-mina-6662371)
- 2026-08-04 20:14 UTC [SEC Form 3] [SEC Form 3 filed by new insider Mina Michael](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-mina-michael-6662339)
- 2026-08-04 11:01 UTC [Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6660942)
- 2026-07-24 20:05 UTC [SEC Form 8-K] [Invivyd Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/invivyd-inc-filed-sec-form-8-k-notice-of-delisting-or-6648296)
- 2026-07-06 11:11 UTC [SEC Form 8-K] [Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/invivyd-inc-filed-sec-form-8-k-other-events-financial-statements-6627247)
- 2026-07-06 11:01 UTC [Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA](https://www.quantisnow.com/insight/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-emergency-6627233)
- 2026-07-02 11:01 UTC [Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6624135)
- 2026-06-29 11:00 UTC [Leadership Update] [NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer](https://www.quantisnow.com/insight/novabridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-officer-6618169)
- 2026-06-16 11:01 UTC [Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine](https://www.quantisnow.com/insight/invivyd-announces-completion-of-enrollment-in-phase-3-liberty-trial-6603838)
- 2026-06-09 11:01 UTC [Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration](https://www.quantisnow.com/insight/invivyd-announces-first-participants-dosed-in-liberty-a-phase-3-6594482)
- 2026-06-03 11:01 UTC [Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6585774)
- 2026-06-01 11:01 UTC [Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID](https://www.quantisnow.com/insight/invivyd-announces-completion-of-enrollment-in-upsized-declaration-clinical-trial-6580534)
- 2026-05-27 11:01 UTC [Conference Announcement] [Invivyd to Participate in Upcoming Investor Events](https://www.quantisnow.com/insight/invivyd-to-participate-in-upcoming-investor-events-6573766)
- 2026-05-21 20:49 UTC [SEC Form 4] [SEC Form 4 filed by Director Royan Ajay](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-royan-ajay-6567912)
- 2026-05-21 20:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Mcguire Terrance](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mcguire-terrance-6567910)
- 2026-05-21 20:49 UTC [SEC Form 4] [SEC Form 4 filed by Director Mclaughlin Kevin F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mclaughlin-kevin-f-6567908)
- 2026-05-21 20:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Elia Marc](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-elia-marc-6567903)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IVVD
- Earnings history: https://www.quantisnow.com/earnings/IVVD
- Dividend history: https://www.quantisnow.com/dividends/IVVD
- Insider transactions: https://www.quantisnow.com/insiders/IVVD
- Options chain: https://www.quantisnow.com/options/IVVD
- SEC 8-K filings only: https://www.quantisnow.com/company/IVVD/8-k
- RSS and alerts for IVVD: https://www.quantisnow.com/docs/rss-feeds.md